阿尔茨海默病临床前阶段脑脊液突触生物标志物及其与MRI和PET的关联:横断面研究
本研究在ALFA+队列中纳入中年认知正常参与者,检测脑脊液突触生物标志物(神经颗粒素、GAP-43、SNAP-25、突触结合蛋白-1)及AD病理和神经退行性标志物,并分析其与年龄、性别、APOE ε4、Aβ负荷、tau病理及神经退行性指标的关系。结果显示所有突触标志物随年龄增长而升高,且在Aβ沉积最早阶段即已升高,并与Aβ负荷、p-tau和NfL相关。
要点
- 脑脊液突触生物标志物在Aβ沉积最早阶段即升高。
- 神经颗粒素女性更高,SNAP-25在APOE ε4携带者更高。
- 神经颗粒素和GAP-43与脑代谢升高及皮层厚度降低相关。
核心结论
- 脑脊液突触生物标志物在阿尔茨海默病连续谱早期临床前阶段即升高,即使Aβ病理负荷较低。
- 不同突触生物标志物与年龄、性别、APOE ε4及神经退行性标志物的关联存在差异。
研究设计与样本
- 横断面研究,基于阿尔茨海默病与家庭(ALFA+)队列,纳入中年认知正常参与者。
- 脑脊液神经颗粒素和GAP-43用免疫分析法测定,SNAP-25和突触结合蛋白-1用免疫沉淀质谱法测定。
- 同时测定脑脊液Aβ42/40、p-tau、总tau和NfL,参与者接受结构MRI、氟脱氧葡萄糖PET和Aβ PET成像。
- 采用一般线性模型检验脑脊液突触生物标志物与危险因素、Aβ病理、tau病理及神经退行性标志物的关联。
主要发现
- 所有脑脊液突触生物标志物均随年龄增长而升高。
- 脑脊液神经颗粒素在女性中更高,脑脊液SNAP-25在APOE ε4携带者中更高。
- 所有脑脊液突触生物标志物随Aβ负荷(脑脊液Aβ42/40和Aβ PET Centiloid值)升高而升高,且在Aβ沉积最早阶段个体中即已升高。
- 较高的脑脊液突触生物标志物与较高的脑脊液p-tau和NfL相关。
- 较高的脑脊液神经颗粒素和GAP-43与AD相关脑区脑代谢升高但皮层厚度降低显著相关。
临床怎么用
- 脑脊液突触生物标志物有助于在临床前阶段识别突触损伤,尤其在Aβ沉积早期。
- 解读突触生物标志物时需考虑年龄、性别和APOE ε4状态的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To determine whether CSF synaptic biomarkers are altered in the early preclinical stage of the Alzheimer continuum and associated with Alzheimer disease (AD) risk factors, primary pathology, and neurodegeneration markers. METHODS: This cross-sectional study was performed in the Alzheimer's and Families (ALFA+) cohort, comprising middle-aged cognitively unimpaired participants. CSF neurogranin and growth-associated protein-43 (GAP-43) were measured with immunoassays, and synaptosomal-associated protein-25 (SNAP-25) and synaptotagmin-1 were measured with immunoprecipitation mass spectrometry. AD CSF biomarkers β-amyloid (Aβ)42/40, phosphorylated tau (p-tau), and total tau and the neurodegeneration biomarker neurofilament light chain (NfL) were also measured. Participants underwent structural MRI and fluorodeoxyglucose and Aβ PET imaging. General linear modeling was used to test the associations between CSF synaptic biomarkers and risk factors, Aβ pathology, tau pathology, and neurodegeneration markers. RESULTS: All CSF synaptic biomarkers increased with age. CSF neurogranin was higher in females, while CSF SNAP-25 was higher in APOE ε4 carriers. All CSF synaptic biomarkers increased with higher Aβ load (as measured by CSF Aβ42/40 and Aβ PET Centiloid values), and it is important to note that the synaptic biomarkers were increased even in individuals in the earliest stages of Aβ deposition. Higher CSF synaptic biomarkers were also associated with higher CSF p-tau and NfL. Higher CSF neurogranin and GAP-43 were significantly associated with higher brain metabolism but lower cortical thickness in AD-related brain regions. DISCUSSION: CSF synaptic biomarkers increase in the early preclinical stages of the Alzheimer continuum even when a low burden of Aβ pathology is present, and they differ in their association with age, sex, APOE ε4, and markers of neurodegeneration. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier NCT02485730.
引用
- Milà-Alomà M, Brinkmalm A, Ashton NJ, et al. CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study. Neurology. 2021. PMID: 34556565. doi:10.1212/WNL.0000000000012853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。